Pharmaceuticals

Global Multiple Myeloma Drugs Market Analysis for 2026–2030 with Strategic Business Insights

March 23, 2026March 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Multiple Myeloma Drugs Market By 2030 Starting From Its 2026 Size?

The multiple myeloma drugs market has experienced robust growth in recent years. It is projected to expand from $23.03 billion in 2025 to $24.4 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.0%. This past growth can be attributed to several factors, including the increasing prevalence of multiple myeloma, the approval of novel immunomodulatory drugs, rising awareness about plasma cell cancers, the development of proteasome inhibitors, and the expansion of hospital pharmacy networks.

The multiple myeloma drugs market is projected to experience substantial growth in the upcoming period. By 2030, this market is forecasted to reach $31.61 billion, exhibiting a compound annual growth rate (CAGR) of 6.7%. Factors contributing to this growth during the forecast period include the increasing adoption of precision medicine, heightened investment in biologic therapies, a growing geriatric population, the broadening reach of online pharmacy distribution, and breakthroughs in monoclonal antibody treatments. Key trends shaping the market over this period encompass the development of personalized therapies, the implementation of combination drug regimens, improved bone health management for multiple myeloma patients, advancements in targeted drug delivery systems, and an expansion in clinical trials.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11943&type=smp

Which Market Drivers Are Supporting The Expansion Of The Multiple Myeloma Drugs Market?

The increasing occurrence of hematological cancer is projected to propel the expansion of the multiple myeloma drugs market moving forward. These cancers originate in blood-forming tissue, such as bone marrow, or in immune system cells, including conditions like leukemia, lymphoma, and multiple myeloma, among others. Multiple myeloma drugs are commonly utilized to address various forms of myeloma by eliminating cancer cells and restricting their growth, primarily by slowing down cell division through stimulating numerous enzymatic processes, as well as by aiding in bone strengthening and alleviating pain in weakened bones. For example, in January 2023, the American Cancer Society (ACS), a US-based health organization dedicated to eradicating cancer, noted approximately 59,610 newly identified cases of leukemia and about 20,380 cases of acute myeloid leukemia (AML). Moreover, the cumulative number of deaths linked to leukemia reached 23,710. Thus, the escalating prevalence of hematological cancer is a key factor driving the growth of the multiple myeloma drugs market.

Which Segment Categories Define The Multiple Myeloma Drugs Market?

The multiple myeloma drugs market covered in this report is segmented –

1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types

2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Men, Women

Subsegments:

1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib

3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin

4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab

5) By Steroids: Dexamethasone, Prednisone

6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs

What Major Market Trends Are Driving Changes In The Multiple Myeloma Drugs Market?

Leading companies in the multiple myeloma drug market are intensifying their collaborative strategies for co-developing cell therapies by broadening their partnerships to expedite the development and market introduction of next-generation CAR T products. Such strategic alliances facilitate shared resources, mitigate risks, and enable quicker scaling for innovative therapies. For instance, in May 2024, Kite Pharma, a US-based biopharmaceutical company, and Arcellx, Inc., a US-based clinical-stage biotechnology company, announced significant operational updates for their partnered BCMA CAR T therapy, anitocabtagene autoleucel (anito cel). The companies disclosed the design of a global Phase 3 trial, named iMMagine 3, intended to evaluate anito cel in patients with relapsed or refractory multiple myeloma who have previously been treated with both an immunomodulatory drug (IMiD) and an anti-CD38 monoclonal antibody. This trial is projected to recruit approximately 450 patients globally.

Who Are The Top Companies Competing In The Multiple Myeloma Drugs Market?

Major companies operating in the multiple myeloma drugs market are Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Onyx Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., PharmaMar SA

Read the full multiple myeloma drugs market report here:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

How Is The Multiple Myeloma Drugs Market Distributed Across Key Geographic Regions?

North America was the largest region in the multiple myeloma drugs market in 2025. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Multiple Myeloma Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11943&type=smp

Browse Through More Reports Similar to the Global Multiple Myeloma Drugs Market 2026, By The Business Research Company

Multiple Myeloma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

Multiple Myeloma Market Report 2026

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795